Aclaris Therapeutics (NasdaqGS:ACRS) FY Conference February 26, 2026 08:40 AM ET Company ParticipantsHugh Davis - President, COO and Member of the Board of DirectorsJesse Hall - Chief Medical OfficerNone - Company RepresentativeConference Call ParticipantsJeff Jones - Senior AnalystJeff JonesGood morning, everyone, and welcome back to day two of Oppenheimer's Annual Healthcare Conference. I'm Jeff Jones, one of the senior analysts on the team here, and I'm delighted to welcome multiple members from the Acla ...

TG Therapeutics (NasdaqCM:TGTX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsAdam Waldman - Chief Commercialization OfficerCorinne Johnson - Vice President of Equity ResearchEmily Bodnar - Vice President of Equity ResearchJenna Bosco - VP of Corporate CommunicationsMichael Weiss - Chairman, President, and CEOSean Power - CFOConference Call ParticipantsBrian Cheng - Vice President and Equity Research AnalystMichael Schmidt - Managing Director and Equity Research AnalystPrakhar Agra ...

Intellia Therapeutics (NasdaqGM:NTLA) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsEdward Dulac - EVP and CFOJason Fredette - Vice President of Investor Relations and Corporate CommunicationsJohn Leonard - President and CEOLidiya Rizova - Associate, Equity ResearchNone - Company RepresentativeConference Call ParticipantsAlec Stranahan - Senior Analyst, Equity ResearchBrian Cheng - Executive Director and Senior Biotech AnalystJack Allen - Senior Research AnalystJonathan Miller - An ...

Chemomab Therapeutics (NasdaqCM:CMMB) FY Conference February 26, 2026 08:00 AM ET Speaker1Good morning, everyone, and welcome back to day two of Oppenheimer's 36th Annual Healthcare Conference. I'm Jeff Jones, one of the biotech analysts on the team here, and I am delighted to welcome Adi Mor, CEO of Chemomab Therapeutics, to give us an update on their story. Adi, I will hand it off to you.Speaker0Thank you very much, Jeff. My pleasure to be here today and presenting Chemomab at the Oppenheimer Conference. ...

HOUSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the BIO Investment & Growth Summit taking place March 2-3, 2026, at the Eden Roc in Miami Beach, FL. FibroB ...

NAPLES, FL / ACCESS Newswire / February 26, 2026 / Stemtech Corporation, the global leader and pioneer in stem cell nutrition, launches Stemtech BioSciences E-Commerce Retail market channel. (Stemtech Corporation - OTCID:STEK) "Live Longer - Live Better - Live Younger" President & COO, John W. ...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), announced that it has executed an agreement with Spaulding Rehabilitation (“Spaulding Rehabilitation”), a member of the Mass General Brigham healthcare system, for the provision of MDMA for use in a clinical trial investigating MDMA-assisted therapy for the trea ...

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 37.2% CAGR since 2017, along with a mid-20s CAGR for our core portfolio LTGP (CAGR performance as of Feb 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

I publish my best ideas and top coverage on the Growth Stock Forum. If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely.Our biotech Top Picks increased 137.6% last year with a 37.2% CAGR since 2017, along with a mid-20s CAGR for our core portfolio LTGP (CAGR performance as of Feb 20, 2026).To receive e-mail notifications for my public articles and blogs, ...

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabio Sonvico. T ...